Botanical Solutions

Botanical Solutions Inc. (BSI) is a biotechnology company that develops sustainable and cost-effective advanced botanical materials (ABMs) for the pharmaceutical and agricultural industries. The company's flagship products are Quillibrium, a biopesticide, and QS-21, a vaccine adjuvant.

Quillibrium is a plant-based fungicide derived from the Quillaja saponaria plant. It has witnessed substantial growth, with over 50% year-over-year increase in effective growers' adoption in Chile and Peru as of October 2023. More than 100,000 acres have been treated with Quillibrium to date. The company has plans to expand the availability of Quillibrium to Mexico, Brazil, the US, and the European Union.

BSI's proprietary platform enables the sustainable and scalable production of plant-based products without sourcing raw materials from nature or conventional plantations. This breakthrough technology has facilitated the development of QS-21, a vaccine adjuvant comparable to the traditional QS-21 obtained from soapbark trees in Chile. QS-21 is utilized in FDA-approved vaccines for shingles, malaria, RSV, and Covid-19, as well as promising new vaccine candidates and immunotherapy treatments for cancer.

In November 2022, BSI received the Best New Biological Product (pesticide) award for Quillibrium at the Crop Science Awards. Additionally, in October 2023, the company was honored with the Best Process Innovation Award from ICIS Chemical Business for its unique platform for sustainable production of plant-based products.

Key customers and partnerships

BSI has established a successful partnership with Syngenta, which began in 2019, for the distribution of Quillibrium. This collaboration has contributed to the significant growth in adoption of the biopesticide.

The company has also forged a partnership with Croda Pharma to meet the pharmaceutical industry's demand for QS-21. This partnership enabled the launch of the next generation of QS-21, providing a reliable and stable supply of this gold standard vaccine adjuvant to Croda Pharma's global customer base.